Metastases are responsible for the vast majority of deaths associated with breast cancer. A recent study reports that a drug used for a long time in cardiology could block the metastatic process at the source and improve the survival of patients.

In recent decades, the discovery of new treatments against breast cancer has made it possible to substantially reduce the mortality rate of this disease, so that at present, more than 95% of women suffering from early forms of Breast cancer (stages 1 and 2) survive more than five years after the diagnosis.

Despite these advances, the fact remains that nearly 685,000 women die every year from breast cancer in the world largely due to the development of incurable metastases in vital organs (mainly lung, brain, liver and bone).

Challenges with Breast Cancer Metastases

This problem associated with metastases is all the more worrying as it has noted that between 2004 and 2021, the incidence of metastatic breast cancers increased by 1.2% each year, including young women aged 20 to 39 years (1).

Other factors exacerbate this challenge. The cost of cancer treatment in the U.S. is astronomical, with annual expenditures exceeding $150 billion. The hunt for new treatments represents both a medical imperative and an economic necessity. Each year, delayed or preventing metastasis could save billions of dollars in healthcare costs and immeasurable human suffering.

The Mechanism of Metastasis

To form metastases, cancer cells must be released from the primary tumor and migrate into the blood circulation towards one or more distant organs.

The body has various organs, and public health experts recognize the prostate, lungs, liver and more to be particularly vulnerable to cancers – including cardiology patients. The migration of these cells influences their chances of success in forming metastases.

Studies have shown that these circulating tumor cells (CTC) have a greater probability of succeeding in forming metastases when they migrate in the form of aggregates containing several cancer cells.

A promising strategy, then, is to dissolve these cell aggregates, potentially braking the vicious cycle of metastasis.

The Role of Digoxin

An examination of 2,486 drugs approved by the American Food and Drug Administration suggests that this approach is promising. Among these, digoxin, a drug derived from a plant, purple digital, and which has been used for more than 100 years to regularize heartbeat, effectively dissolves CTC clusters into individual cells and leads to a removal of metastases in breast cancer models (2).

Dissolving Cell Aggregates

The drug mechanism: Digoxin is a powerful inhibitor of an enzyme that helps regulate electrical potentials. When this enzyme is inhibited, the membrane potential changes dramatically. This causes a massive influx of calcium, destabilizing the cohesion between cancer cells and resulting in the breakup of aggregates.

A New Hope for Patients

To assess whether this approach is applicable to humans, a team of researchers administered digoxin daily to 9 patients with incurable metastatic breast cancer (3) for seven days.

To validate the efficacy of digoxin, researchers administered the drug to nine patients with incurable metastatic breast cancer daily for seven days. By comparing the aggregates of circulating cancer cells in treated patients to those who received a placebo, researchers noted a significant drop in the number of cancer cells present in cellular clumps, especially in women who had the highest blood concentrations of the drug. Though promising, it underscores the need for further investigation, suggesting the implications of ongoing research, including the refinement of treatment protocols to optimize therapeutic outcomes.

Further Research and Implications for Detected Metastases Early On

While this preliminary study focused on establishing the applicability of dissolving circulating cancer cell aggregates in patients with metastatic cancer, it paves the way for future studies involving patients with less advanced cancer. These studies will determine whether this approach can improve survival probabilities, reinforcing the critical importance of early detection and intervention. External organization like the National Breast Cancer Foundation equally important, continuously campaigns for breast exams and screenings. Though the majority of research points to encouraging directions, this remains a symptom of the broader need fully leveraging modern medical innovations. As seen in Metastatic breast cancer is most treatable when it’s detected! from First Lady Jill Biden, National Breast Cancer Awareness Month September 2023

Conclusions and Future Directions

The identification of certain proteins essential to the growth of breast cancer cells has led to the development of new drugs specifically targeting these proteins. Herceptin, for example, has been developed to neutralize a receptor that contributes to the progression of certain forms of breast cancer, and this medication has saved countless lives since its approval. Future research and clinical trials will likely explore the use of digoxin in combination with other therapies, potentially enhancing its effects and broadening its applicability. Digital health platforms, including apps and online resources, can also play a significant role in patient education, monitoring, and adherence to treatment regimens,lude thus generating more accurate biopsies, And as this future opens up, Breast Cancer Foundation continuously stresses yet, earlier and more accurate prognosis is key.